Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients Journal Article

   


Authors: Blouin, A. G.; Hsu, M.; Fleisher, M.; Ramanathan, L. V.; Pastores, S. M.
Article Title: Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients
Abstract: Background: We evaluated the diagnostic utility of procalcitonin (PCT) in predicting bacterial bloodstream infections (BSI) in critically ill cancer patients with and without neutropenia. We also investigated the role of PCT as a prognostic marker of supportive modalities (vasopressors, invasive mechanical ventilation, and renal replacement therapy (RRT)) in the intensive care unit (ICU). Methods: We retrospectively analyzed 2200 PCT and blood cultures from adult cancer patients with suspected sepsis. Primary outcome was BSI, defined by positive blood culture, collected within 72 h of PCT collection. Results: Median PCT values were higher in encounters with BSI (3.2 vs 0.5 ng/ml, p < 0.001). The area under the ROC curve (AUC) was 0.726 (95%CI 0.698, 0.754). PCT > 2.0 ng/ml was significantly associated with greater likelihood of BSI and this effect was significantly stronger for neutropenic (OR 9.09, 95%CI: 4.39, 18.79) compared with non-neutropenic patients (OR 4.00 (95% CI: 3.13, 5.10), interaction p = 0.036). PCT > 2.0 was associated with vasopressor requirement on ICU admission (OR 1.82 (95% CI 1.31, 2.53), p < 0.001) and RRT (OR 2.20 (95% CI 1.24, 3.91), p = 0.007). Conclusions: Procalcitonin is a fair discriminator of BSI in critically ill cancer patients with and without neutropenia and a PCT > 2.0 ng/ml was significantly more likely to require vasopressors and RRT in the ICU. © 2020 Elsevier B.V.
Keywords: adult; controlled study; aged; major clinical study; neutropenia; disease marker; cancer patient; outcome assessment; sensitivity and specificity; biomarkers; protein blood level; disease association; cohort analysis; retrospective study; intensive care unit; sepsis; hospital admission; bloodstream infection; protein determination; predictive value; receiver operating characteristic; hypertensive factor; artificial ventilation; reference value; critically ill patient; diagnostic test accuracy study; blood culture; invasive procedure; renal replacement therapy; procalcitonin; cancer; prognosis; human; male; female; priority journal; article
Journal Title: Clinica Chimica Acta
Volume: 510
ISSN: 0009-8981
Publisher: Elsevier Science BV  
Date Published: 2020-11-01
Start Page: 181
End Page: 185
Language: English
DOI: 10.1016/j.cca.2020.07.024
PUBMED: 32679129
PROVIDER: scopus
PMCID: PMC7572786
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088133236&doi=10.1016%2fj.cca.2020.07.024&partnerID=40&md5=7be9158384d0fed8e9ac77064d79b509
Notes: Article -- Export Date: 3 August 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Meier Hsu
    169 Hsu
  2. Stephen Pastores
    249 Pastores
  3. Martin Fleisher
    312 Fleisher
  4. Lakshmi Vulimiri Ramanathan
    77 Ramanathan
  5. Amanda Germaine Blouin
    21 Blouin
Related MSK Work